Alexandre Bazinet

Hematology

1515 Holcombe Blvd Unit 428
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 23, 2026

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 11, 2026

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Journal: Haematologica

Published: April 22, 2026

Outcomes of patients diagnosed with myelodysplastic syndrome or acute myeloid leukemia following solid organ transplantation.

Outcomes of patients diagnosed with myelodysplastic syndrome or acute myeloid leukemia following solid organ transplantation.

Journal: Haematologica

Published: March 10, 2026

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

Journal: Blood advances

Published: February 25, 2026

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

Journal: Blood advances

Published: February 25, 2026

Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.

Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.

Journal: American journal of hematology

Published: February 09, 2026

Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL.

Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL.

Journal: American journal of hematology

Published: February 01, 2026

Mutations in Isocitrate Dehydrogenase Portend a Poor Prognosis in Adult Patients with Acute Lymphoblastic Leukemia.

Mutations in Isocitrate Dehydrogenase Portend a Poor Prognosis in Adult Patients with Acute Lymphoblastic Leukemia.

Journal: Blood advances

Published: January 02, 2026

Mutations in isocitrate dehydrogenase portend a poor prognosis in adult patients with acute lymphoblastic leukemia.

Mutations in isocitrate dehydrogenase portend a poor prognosis in adult patients with acute lymphoblastic leukemia.

Journal: Blood advances

Published: January 02, 2026

Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes.

Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes.

Journal: Blood cancer journal

Published: December 04, 2025

Evaluating the Impact of Fewer Frontline Intensive Chemotherapy Plus Venetoclax Consolidation Cycles on Outcomes in AML.

Evaluating the Impact of Fewer Frontline Intensive Chemotherapy Plus Venetoclax Consolidation Cycles on Outcomes in AML.

Journal: American journal of hematology

Published: November 18, 2025

Showing 1-12 of 67

Last Updated: 09/26/2026